Pioneering Medical Innovations
Strategic promotion underscores commitment to commercial growth across Ocular portfolio BEDFORD, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical
Phase 3 SOL-1 study will evaluate the efficacy and safety of AXPAXLI in wet AMD BEDFORD, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE)
SPA amendment expands eligibility criteria for SOL clinical trial Broadening of eligibility criteria anticipated to accelerate overall trial enrollment BEDFORD,
— Topline results of the second Phase 3 clinical trial expected by the end of March — — NDA submission
OTX-DP Demonstrated Statistically Significant Therapeutic Effect for Ocular Itching and Conjunctival Redness over Six Weeks with a Single Dose BEDFORD,
Ocular Therapeutix, which develops and markets eye therapeutics using its sustained-release hydrogel platform, filed on Friday with the SEC to
Study will evaluate reduction in intraocular pressure and product retention. Ocular Therapeutix, Inc. announced today the commencement of a sustained
Ocular Therapeutix, Inc. announced today that it has received IDE approval from the U.S. Food and Drug Administration to conduct
Ocular Therapeutix, Inc. announced today that it has closed a $14 million Series D round of financing. The round was
Plugs achieved 100% retention and demonstrated sustained levels of moxifloxacin throughout the 10-day treatment period. Ocular Therapeutix, Inc. announced today